Literature DB >> 8151183

Low predictive value of PGL-I serology for the early diagnosis of leprosy in family contacts: results of a 10-year prospective field study in French Polynesia.

S Chanteau1, P Glaziou, C Plichart, P Luquiaud, R Plichart, J F Faucher, J L Cartel.   

Abstract

In 1983, a cohort study to follow up the family contacts of leprosy cases was implemented in French Polynesia to assess the usefulness and applicability of phenolic glycolipid-I (PGL-I) serology in a leprosy control program. A total of 1201 contacts (666 females, 535 males) have been included in the study. The IgM anti-PGL-I seroprevalence determined on the initial sera was 17%. It was significantly higher among females than males (20% vs 15%, p = 0.02). From 1983 to 1992, 4 out of 204 (2%) anti-PGL-I seropositive contacts developed the disease (1 indeterminate, 1 BT, 1 BL, 1 LL) compared with 10 out of 997 (1%) seronegative contacts (4 indeterminate, 3 BT, 1 BB, 2 TT). Of these 10 patients, only 3 (2 indeterminate, 1 BT) converted to seropositivity when leprosy was diagnosed. The risk of developing leprosy was not significantly higher among seropositive than among seronegative groups (2% vs 1%, p = 0.2). A PGL-I circulating antigen test performed on 216 selected sera at entry into the trial showed a higher antigen prevalence when the antibody level was higher. PGL-I antigen was detectable in 5 of 12 patients tested prior to diagnosis (1 LL, 1 BL, 3 indeterminate). The median time to externalize the disease was not significantly different among antibody-positive and -negative contacts (17 vs 25 months, p = 0.3). The relative risk of developing leprosy for contact individuals was 30.8 times that of noncontacts, and 15% of the total new cases detected between 1983 and 1992 emerged from the study population.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8151183

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  12 in total

1.  Prospective study of serological conversion as a risk factor for development of leprosy among household contacts.

Authors:  J T Douglas; R V Cellona; T T Fajardo; R M Abalos; M V F Balagon; P R Klatser
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

2.  Use of protein antigens for early serological diagnosis of leprosy.

Authors:  Malcolm S Duthie; Wakako Goto; Greg C Ireton; Stephen T Reece; Ludimila P V Cardoso; Celina M T Martelli; Mariane M A Stefani; Maria Nakatani; Robson Crusue de Jesus; Eduardo M Netto; Ma V F Balagon; Esterlina Tan; Robert H Gelber; Yumi Maeda; Masahiko Makino; Dan Hoft; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2007-09-26

3.  Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial.

Authors:  F Johannes Moet; David Pahan; Linda Oskam; Jan H Richardus
Journal:  BMJ       Date:  2008-03-10

4.  Epidemiology of Nontuberculous Mycobacteria in French Polynesia.

Authors:  Michael Phelippeau; Djaltou Aboubaker Osman; Didier Musso; Michel Drancourt
Journal:  J Clin Microbiol       Date:  2015-12       Impact factor: 5.948

5.  Serological diagnosis of leprosy in patients in vietnam by enzyme-linked immunosorbent assay with Mycobacterium leprae-derived major membrane protein II.

Authors:  Masanori Kai; Nhu Ha Nguyen Phuc; Thuy Huong Hoang Thi; An Hoang Nguyen; Yasuo Fukutomi; Yumi Maeda; Yuji Miyamoto; Tetsu Mukai; Tsuyoshi Fujiwara; Tan Thanh Nguyen; Masahiko Makino
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

6.  Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis.

Authors:  Malcolm S Duthie; Greg C Ireton; Ganga V Kanaujia; Wakako Goto; Hong Liang; Ajay Bhatia; Jean Marie Busceti; Murdo Macdonald; Kapil Dev Neupane; Chaman Ranjit; Bishwa Raj Sapkota; Marivic Balagon; Javan Esfandiari; Darrick Carter; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2008-08-20

7.  ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy.

Authors:  Stephen T Reece; Greg Ireton; Raodoh Mohamath; Jeffrey Guderian; Wakako Goto; Robert Gelber; Nathan Groathouse; John Spencer; Patrick Brennan; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2006-03

8.  Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study.

Authors:  Nádia C Düppre; Luiz Antonio B Camacho; Anna M Sales; Ximena Illarramendi; José Augusto C Nery; Elizabeth P Sampaio; Euzenir N Sarno; Samira Bührer-Sékula
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

9.  Nasal mucosa study of leprosy contacts with positive serology for the phenolic glycolipid 1 antigen.

Authors:  Ana Cristina da Costa Martins; Alice Miranda; Maria Leide Wan-del-Rey de Oliveira; Samira Bührer-Sékula; Alejandra Martinez
Journal:  Braz J Otorhinolaryngol       Date:  2010 Sep-Oct

Review 10.  Anti-PGL-1 Positivity as a Risk Marker for the Development of Leprosy among Contacts of Leprosy Cases: Systematic Review and Meta-analysis.

Authors:  Maria Lucia F Penna; Gerson O Penna; Paula C Iglesias; Sonia Natal; Laura C Rodrigues
Journal:  PLoS Negl Trop Dis       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.